Abstract
Background The impact of human papillomavirus (HPV) vaccination programs depends on the degree of indirect protection against new infections achieved among unvaccinated women. We estimated the indirect effect of bivalent HPV vaccination by comparing the HPV-type incidence in unvaccinated female participants between a cohort offered vaccination in 2009/10 and a cohort of similar aged women offered vaccination in 2014.
Methods We compared the incidence rates of HPV types in the HAVANA cohort (follow-up from 2010/11 until 2015/16) with those from the HAVANA-2 cohort (2017-2022) using two regression approaches to estimate the indirect effect of HPV vaccination. First, we calculated the incidence ratio (IRR) for a vaccine or cross-protective type in HAVANA-2 versus HAVANA by Poisson regression and compared it to the IRR for a non-cross-protective type. The indirect vaccine effect is defined as 1-ratio of the IRRs. Second, we performed Cox regression with infection by vaccine or cross-protective type as the endpoint and calculated the hazard ratio (HR) for HAVANA-2 versus HAVANA after adjusting for time-varying sociodemographic variables. The indirect effect is defined as 1-HR.
Results We included 661 unvaccinated participants in HAVANA and 927 in HAVANA-2. We observed a significant reduction in incident HPV16 infections of 70.9% (95% CI 48.3–83.7%) with Poisson regression and of 73.1% (95% CI 53.3–84.5%) with Cox regression. For HPV45, significant decreases of 67.3% (95% CI 8.8–88.3%) and 69.8% (95% CI 15.2–89.3%) were observed. For HPV18, HPV31, and HPV33, the indirect effect was not statistically significant.
Conclusions Large indirect effects of the bivalent HPV vaccination program were observed for HPV16 and HPV45 infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Dutch Ministry of Health, Welfare, and Sport. The funder had no role in the design, data collection, data analysis, and reporting of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Amsterdam University Medical Center (UMC), the Netherlands, gave ethical approval for this work (nr: 2009/022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Aggregated data that support the findings of this study are available upon reasonable request from the corresponding author.
List of abbreviations
- HPV
- human papillomavirus
- IRR
- incidence rate ratio
- HR
- hazard ratio
- 2vHPV
- bivalent HPV
- 3D
- 3-dose
- 2D
- 2-dose
- CIN3
- cervical intraepithelial neoplasia grade 3
- HAVANA study
- HPV Amongst Vaccinated and Non-vaccinated Adolescents study
- CI
- confidence intervals
- PH
- proportional hazard
- HR
- hazard ratio
